Lisco et al. considered eleven clinical trials and concluded that Tirzepatide provides a weight loss that exceeds that obtained with GLP-1 receptor agonists; hence, Tirzepatide is presented as a potent tool to improve glucose control without increasing hypoglycemic risk in poorly controlled T2DM treated with basal insulin with or without other hypoglycemic oral agents with effects on body weight loss, despite the background therapy [83]. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.